经导管眼动脉灌注化疗治疗晚期视网膜母细胞瘤30例

发布时间：2018-03-27 20:41

本文选题：视网膜母细胞瘤　切入点：眼动脉　出处：《介入放射学杂志》2014年01期

【摘要】：目的评估经导管眼动脉灌注化疗术的(TOAC)治疗眼内晚期化疗失败的视网膜母细胞瘤的临床疗效及安全性。方法回顾性分析2009年1月—2011年4月收治的经化疗失败的视网膜母细胞瘤患儿30例39只患眼行SOAI治疗的临床资料。39只患眼共行TOAC术82次,平均每眼行2.1次,随访时间2~28个月,平均13.6个月。术后评估肿瘤控制的有效率、并发症及有无局部肿瘤进展。结果 84次眼动脉插管中,82次成功插至眼动脉,技术成功率为97.6%。术后30只眼肿瘤有不同程度的缩小,有效率76.9%,其中D期、E期分别为17、13只眼,分别占同期治疗眼的85.0%、68.4%;其余9只眼(9/39,23.1%)行眼球摘除。TOAC术后10只眼(10/39,25.6%)出现过球结膜充血,7只眼(7/39,17.9%)发生眼睑肿胀,3只眼(3/39,7.7%)多泪,均自行恢复。全部患儿均未出现血流感染等严重全身并发症。结论TOAC是治疗眼内晚期化疗失败的视网膜母细胞瘤的安全有效的治疗方法。
[Abstract]:Objective to evaluate the clinical efficacy and safety of transcatheter ophthalmic arterial infusion chemotherapy (TOAC) in the treatment of retinoblastoma with late intraocular chemotherapy failure. Methods from January 2009 to April 2011, the clinical efficacy and safety of chemotherapy failed retinoblastoma were analyzed retrospectively. Clinical data of 39 eyes of 30 cases with retinoblastoma treated with SOAI. 39 eyes were treated with TOAC for 82 times. The average time was 2.1 times per eye, and the follow-up time was 2 ~ 28 months (mean 13.6 months). The effective rate of tumor control, complications and local tumor progression were evaluated after operation. Results 82 times of 84 ophthalmic arterial catheterization were successfully inserted into the ophthalmic artery. The technical success rate was 97.60.Thirty eye tumors were reduced in varying degrees, and the effective rate was 76.9. among them, 17 eyes were in stage D and 13 eyes were in stage E, respectively. 85.0% of the eyes treated in the same period accounted for 68.4%; the other 9 eyes (9% 39.23. 1) were treated with 10 / 39% 25.6% of the 10 eyes after TOAC.) there were 7 eyes with bulbar conjunctival hyperemia and 7 eyes with bulbar conjunctival congestion (739% 17.9%). Conclusion TOAC is a safe and effective method for the treatment of retinoblastoma with late intraocular chemotherapy failure.
【作者单位】：广州市妇女儿童医疗中心介入血管瘤科;上海交通大学医学院附属新华医院放射科;
【基金】：广州市科技和信息化局科学技术基金课题(2012J4100032)
【分类号】：R739.7

【共引文献】